Skip to main content
Top
Published in: Digestive Diseases and Sciences 5/2024

Open Access 24-02-2024 | Irritable Bowel Syndrome | Original Article

Healthcare Utilization Patterns: Irritable Bowel Syndrome, Inflammatory Bowel Disease, and Gastroesophageal Reflux Disease

Authors: Natasha Koloski, Ayesha Shah, Iain Kaan, Ronen Ben Jacob, Nicholas J. Talley, Michael P. Jones, Gerald Holtmann

Published in: Digestive Diseases and Sciences | Issue 5/2024

Login to get access

Abstract

Background

Limited information is available about patterns of healthcare utilization for prevalent gastrointestinal conditions and their link to symptom burden.

Aim

To identify patterns of healthcare utilization among outpatients with highly prevalent gastrointestinal conditions and define the link between healthcare utilization, symptom burden, and disease group.

Methods

We randomly selected patients from the gastroenterology outpatient clinic at Princess Alexandra Hospital who had chronic gastrointestinal conditions such as constipation-predominant irritable bowel syndrome (IBS-C, n = 101), diarrhea-predominant IBS (IBS-D, n = 101), mixed IBS (n = 103), inflammatory bowel disease with acute flare (n = 113), IBD in remission (n = 103), and gastroesophageal reflux disease (n = 102). All had presented at least 12 months before and had a 12-month follow-up after the index consultation. Healthcare utilization data were obtained from state-wide electronic medical records over a 24-month period. Intensity of gastrointestinal symptoms was measured using the validated Structured Assessment of Gastrointestinal Symptoms (SAGIS) Scale. Latent class analyses (LCA) based on healthcare utilization were used to identify distinct patterns of healthcare utilization among these patients.

Results

LCA revealed four distinct healthcare utilization patterns across all diagnostic groups: Group A: Emergency department utilizers, Group B: Outpatient focused care utilizers, Group C: Inpatient care utilizers and Group D: Inpatient care and emergency department utilizers. LCA groups with high emergency utilization were characterized by high gastrointestinal symptom burden at index consultation regardless of condition (Mean (standard deviation)) SAGIS score Group A: 24.63 (± 14.11), Group B: 19.18 (± 15.77), Group C: 22.48 (± 17.42), and Group D: 17.59 (± 13.74, p < 0.05).

Conclusion

Distinct healthcare utilization patterns across highly prevalent gastrointestinal conditions exist. Symptom severity rather than diagnosis, likely reflecting unmet clinical need, defines healthcare utilization.
Literature
1.
go back to reference Richter JE, Rubenstein JH. Presentation and epidemiology of gastroesophageal reflux disease. Gastroenterology 2018;154:267–276.CrossRefPubMed Richter JE, Rubenstein JH. Presentation and epidemiology of gastroesophageal reflux disease. Gastroenterology 2018;154:267–276.CrossRefPubMed
2.
go back to reference Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology 2017;152:313–21.e2.CrossRefPubMed Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology 2017;152:313–21.e2.CrossRefPubMed
3.
go back to reference Sperber AD, Bangdiwala SI, Drossman DA et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study. Gastroenterology 2021;160:99-114.e3.CrossRefPubMed Sperber AD, Bangdiwala SI, Drossman DA et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study. Gastroenterology 2021;160:99-114.e3.CrossRefPubMed
4.
go back to reference Burisch J, Jess T, Martinato M et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013;7:322–337.CrossRefPubMed Burisch J, Jess T, Martinato M et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013;7:322–337.CrossRefPubMed
5.
go back to reference Gikas A, Triantafillidis JK. The role of primary care physicians in early diagnosis and treatment of chronic gastrointestinal diseases. Int J Gen Med 2014;7:159–173.CrossRefPubMedPubMedCentral Gikas A, Triantafillidis JK. The role of primary care physicians in early diagnosis and treatment of chronic gastrointestinal diseases. Int J Gen Med 2014;7:159–173.CrossRefPubMedPubMedCentral
6.
go back to reference Wammes JJG, Tanke M, Jonkers W et al. Characteristics and healthcare utilisation patterns of high-cost beneficiaries in the Netherlands: a cross-sectional claims database study. BMJ Open 2017;7:e017775.CrossRefPubMedPubMedCentral Wammes JJG, Tanke M, Jonkers W et al. Characteristics and healthcare utilisation patterns of high-cost beneficiaries in the Netherlands: a cross-sectional claims database study. BMJ Open 2017;7:e017775.CrossRefPubMedPubMedCentral
7.
go back to reference Lacy B, Ayyagari R, Guerin A et al. Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndrome. Therap Adv Gastroenterol 2019;12:1–17.CrossRef Lacy B, Ayyagari R, Guerin A et al. Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndrome. Therap Adv Gastroenterol 2019;12:1–17.CrossRef
8.
go back to reference Peery AF, Crockett SD, Murphy CC et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology 2019;156:254–72.e11.CrossRefPubMed Peery AF, Crockett SD, Murphy CC et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology 2019;156:254–72.e11.CrossRefPubMed
9.
go back to reference Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006 Aug;101(8):1900–20 Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006 Aug;101(8):1900–20
10.
go back to reference Koloski NA, Jones M, Hammer J et al. The validity of a new Structured Assessment of Gastrointestinal Symptoms Scale (SAGIS) for evaluating symptoms in the clinical setting. Dig Dis Sci 2017;62:1913–1922.CrossRefPubMed Koloski NA, Jones M, Hammer J et al. The validity of a new Structured Assessment of Gastrointestinal Symptoms Scale (SAGIS) for evaluating symptoms in the clinical setting. Dig Dis Sci 2017;62:1913–1922.CrossRefPubMed
11.
go back to reference Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther 2014;40:1023–1034.CrossRefPubMed Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther 2014;40:1023–1034.CrossRefPubMed
12.
go back to reference Park KT, Ehrlich OG, Allen JI et al. The cost of inflammatory bowel disease: an initiative from the Crohn’s & Colitis Foundation. Inflamm Bowel Dis 2020;26:1–10.CrossRefPubMed Park KT, Ehrlich OG, Allen JI et al. The cost of inflammatory bowel disease: an initiative from the Crohn’s & Colitis Foundation. Inflamm Bowel Dis 2020;26:1–10.CrossRefPubMed
13.
go back to reference Gawron AJ, French DD, Pandolfino JE et al. Economic evaluations of gastroesophageal reflux disease medical management. Pharmacoeconomics 2014;32:745–758.CrossRefPubMedPubMedCentral Gawron AJ, French DD, Pandolfino JE et al. Economic evaluations of gastroesophageal reflux disease medical management. Pharmacoeconomics 2014;32:745–758.CrossRefPubMedPubMedCentral
14.
go back to reference McKenzie H, Hayes L, White K et al. Chemotherapy outpatients’ unplanned presentations to hospital: a retrospective study. Support Care Cancer 2011;19:963–969.CrossRefPubMed McKenzie H, Hayes L, White K et al. Chemotherapy outpatients’ unplanned presentations to hospital: a retrospective study. Support Care Cancer 2011;19:963–969.CrossRefPubMed
15.
go back to reference Qin D, Yue L, Xue B, et al. Pharmacological treatments for patients with irritable bowel syndrome. An umbrella review of systematic reviews and meta-analyses. Medicine (Baltimore) 2019;98:e15920. Qin D, Yue L, Xue B, et al. Pharmacological treatments for patients with irritable bowel syndrome. An umbrella review of systematic reviews and meta-analyses. Medicine (Baltimore) 2019;98:e15920.
16.
go back to reference Black CJ, Burr NE, Quigley EMM et al. Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: systematic review and network meta-analysis. Gastroenterology 2018;155:1753–1763.CrossRefPubMed Black CJ, Burr NE, Quigley EMM et al. Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: systematic review and network meta-analysis. Gastroenterology 2018;155:1753–1763.CrossRefPubMed
17.
go back to reference McKenzie YA, Bowyer RK, Leach H et al. British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet 2016;29:549–575.CrossRefPubMed McKenzie YA, Bowyer RK, Leach H et al. British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet 2016;29:549–575.CrossRefPubMed
18.
go back to reference Ford AC, Harris LA, Lacy BE et al. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther 2018;48:1044–1060.CrossRefPubMed Ford AC, Harris LA, Lacy BE et al. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther 2018;48:1044–1060.CrossRefPubMed
19.
go back to reference Bray N, Koloski NA, Jones MP et al. A multidisciplinary integrated treatment approach is superior to standard care for functional gastrointestinal disorders (FGIDs): a case-control study [abstract]. Gastroenterology 2019;156:273. Bray N, Koloski NA, Jones MP et al. A multidisciplinary integrated treatment approach is superior to standard care for functional gastrointestinal disorders (FGIDs): a case-control study [abstract]. Gastroenterology 2019;156:273.
20.
21.
go back to reference Longstreth GF, Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology 2004;126:1665–1673.CrossRefPubMed Longstreth GF, Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology 2004;126:1665–1673.CrossRefPubMed
22.
go back to reference Levy RL, Von Korff M, Whitehead WE et al. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001;96:3122–3129.CrossRefPubMed Levy RL, Von Korff M, Whitehead WE et al. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001;96:3122–3129.CrossRefPubMed
23.
go back to reference Flik CE, Laan W, Smout AJPM et al. Comparison of medical costs generated by IBS patients in primary and secondary care in the Netherlands. BMC Gastroenterol 2015;15:168.CrossRefPubMedPubMedCentral Flik CE, Laan W, Smout AJPM et al. Comparison of medical costs generated by IBS patients in primary and secondary care in the Netherlands. BMC Gastroenterol 2015;15:168.CrossRefPubMedPubMedCentral
24.
go back to reference Tack J, Stanghellini V, Mearin F et al. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries. BMC Gastroenterol 2019;19:69.CrossRefPubMedPubMedCentral Tack J, Stanghellini V, Mearin F et al. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries. BMC Gastroenterol 2019;19:69.CrossRefPubMedPubMedCentral
25.
go back to reference Gudleski GD, Satchidanand N, Dunlap LJ et al. Predictors of medical and mental health care use in patients with irritable bowel syndrome in the United States. Behav Res Ther 2017;88:65–75.CrossRefPubMedPubMedCentral Gudleski GD, Satchidanand N, Dunlap LJ et al. Predictors of medical and mental health care use in patients with irritable bowel syndrome in the United States. Behav Res Ther 2017;88:65–75.CrossRefPubMedPubMedCentral
26.
go back to reference Van den Houte K, Carbone F, Pannemans J et al. Prevalence and impact of self-reported irritable bowel symptoms in the general population. United European Gastroenterol J 2019;7:307–315.CrossRefPubMed Van den Houte K, Carbone F, Pannemans J et al. Prevalence and impact of self-reported irritable bowel symptoms in the general population. United European Gastroenterol J 2019;7:307–315.CrossRefPubMed
27.
go back to reference Moayyedi P, Simrén M, Bercik P. Evidence-based and mechanistic insights into exclusion diets for IBS. Nat Rev Gastroenterol Hepatol 2020;17:406–413.CrossRefPubMed Moayyedi P, Simrén M, Bercik P. Evidence-based and mechanistic insights into exclusion diets for IBS. Nat Rev Gastroenterol Hepatol 2020;17:406–413.CrossRefPubMed
28.
go back to reference Koloski NA, Talley NJ, Boyce PM. The impact of functional gastrointestinal disorders on quality of life. Am J Gastroenterol 2000;95:67–71.CrossRefPubMed Koloski NA, Talley NJ, Boyce PM. The impact of functional gastrointestinal disorders on quality of life. Am J Gastroenterol 2000;95:67–71.CrossRefPubMed
29.
go back to reference Gralnek IM, Hays RD, Kilbourne A et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000;119:654–660.CrossRefPubMed Gralnek IM, Hays RD, Kilbourne A et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000;119:654–660.CrossRefPubMed
30.
go back to reference Faresjö Å, Walter S, Norlin AK et al. Gastrointestinal symptoms - an illness burden that affects daily work in patients with IBS. Health Qual Life Outcomes 2019;17:113.CrossRefPubMedPubMedCentral Faresjö Å, Walter S, Norlin AK et al. Gastrointestinal symptoms - an illness burden that affects daily work in patients with IBS. Health Qual Life Outcomes 2019;17:113.CrossRefPubMedPubMedCentral
31.
go back to reference Paré P, Gray J, Lam S et al. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: Baseline results from logic (longitudinal outcomes study of gastrointestinal symptoms in Canada), a naturalistic study. Clin Ther 2006;28:1726–1735.CrossRefPubMed Paré P, Gray J, Lam S et al. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: Baseline results from logic (longitudinal outcomes study of gastrointestinal symptoms in Canada), a naturalistic study. Clin Ther 2006;28:1726–1735.CrossRefPubMed
32.
go back to reference Layer P, Andresen V, Pehl C, et al. [Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management]. Z Gastroenterol 2011;49:237–93. Layer P, Andresen V, Pehl C, et al. [Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management]. Z Gastroenterol 2011;49:237–93.
33.
go back to reference Fock KM, Talley N, Goh KL et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett’s oesophagus. Gut 2016;65:1402–1415.CrossRefPubMed Fock KM, Talley N, Goh KL et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett’s oesophagus. Gut 2016;65:1402–1415.CrossRefPubMed
34.
go back to reference Modlin IM, Hunt RH, Malfertheiner P et al. Diagnosis and management of non-erosive reflux disease – the Vevey NERD Consensus Group. Digestion 2009;80:74–88.CrossRefPubMedPubMedCentral Modlin IM, Hunt RH, Malfertheiner P et al. Diagnosis and management of non-erosive reflux disease – the Vevey NERD Consensus Group. Digestion 2009;80:74–88.CrossRefPubMedPubMedCentral
35.
go back to reference Pieper C, Haag S, Gesenhues S et al. Guideline adherence and patient satisfaction in the treatment of inflammatory bowel disorders – an evaluation study. BMC Health Serv Res 2009;9:17.CrossRefPubMedPubMedCentral Pieper C, Haag S, Gesenhues S et al. Guideline adherence and patient satisfaction in the treatment of inflammatory bowel disorders – an evaluation study. BMC Health Serv Res 2009;9:17.CrossRefPubMedPubMedCentral
36.
go back to reference Koloski NA, Talley NJ, Boyce PM. Epidemiology and health care seeking in the functional GI disorders: a population-based study. Am J Gastroenterol Suppl 2002;97(9):2290–2299.CrossRef Koloski NA, Talley NJ, Boyce PM. Epidemiology and health care seeking in the functional GI disorders: a population-based study. Am J Gastroenterol Suppl 2002;97(9):2290–2299.CrossRef
37.
Metadata
Title
Healthcare Utilization Patterns: Irritable Bowel Syndrome, Inflammatory Bowel Disease, and Gastroesophageal Reflux Disease
Authors
Natasha Koloski
Ayesha Shah
Iain Kaan
Ronen Ben Jacob
Nicholas J. Talley
Michael P. Jones
Gerald Holtmann
Publication date
24-02-2024
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 5/2024
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-024-08297-w

Other articles of this Issue 5/2024

Digestive Diseases and Sciences 5/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.